ArticleBiochemistry research international2026
Prognostic Significance and Immune Correlation of CCL3 Expression in Colon Adenocarcinoma: Insights From Multidatabase Analysis.
Article in Biochemistry research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Significance and Immune Correlation of CCL3 Expression in Colon Adenocarcinoma: Insights From Multidatabase Analysis.Biochemistry research international · 2026Article
- Cytokine and chemokine networks in colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Colon adenocarcinoma (COAD) remains a leading cause of cancer-related mortality, necessitating reliable prognostic biomarkers. This study explored the potential prognostic role of C-C motif chemokine ligand 3 (CCL3) and its association with immune-related signatures in COAD. Methods: Multiple publicly accessible databases, including TCGA, GEPIA2, UALCAN, TIMER, and Kaplan-Meier (KM) plotter, were used to examine the expression and prognostic profiles of CCL3 in various cancers. The association between CCL3 expression and clinical stage, immune infiltration, and immune gene markers was investigated using TIMER, GEPIA2, and TISIDB databases. Furthermore, we conducted functional enrichment analyses (GO and KEGG) of genes coexpressed with CCL3, assessed methylation status using OncoBD and MEXPRESS, and developed a gene-miRNA interaction network using miRWalk to elucidate their potential roles in COAD. Results: The expression of CCL3 was significantly upregulated in COAD and most other malignancies. Furthermore, high CCL3 expression was significantly associated with poor overall survival (OS) and relapse-free survival (RFS), with a univariate HR = 1.52 (95% CI: 1.12-2.06, Conclusion: This study suggests that CCL3 could serve as a potential prognostic marker for COAD and other cancers. Because CCL3 expression was strongly associated with immune modulation within the tumor microenvironment, this pointed out that CCL3 could serve as a promising therapeutic target with significant implications for immunotherapy and chemotherapy response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.